1. Racial characteristics of FTC/TDF for pre-exposure prophylaxis (PrEP) users in the US;Bush;ASM Microbe/ICAAC,2016
2. Center for Disease Control and Prevention. (2019). Pre-exposure prophylaxis. Retrieved from https://www.cdc.gov/hiv/risk/prep/index.html
3. Federal Drug Administration. (2012). Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use. Retrieved from: https://www.fda.gov/media/83586/download
4. Gilead Sciences, Inc. (2018). U.S. Food and Drug Administration approves expanded indication for Truvada® (emtricitabine and tenofovir disoproxil fumarate) for reducing the risk of acquiring HIV-1 in adolescents. Retrieved fromhttp://www.gilead.com/news/press-releases/2018/5/us-food-and-drug-administration-approves-expanded-indication-for-truvada-emtricitabine-and-tenofovir-disoproxil-fumarate-for-reducing-the-risk-of-acquiring-hiv1-in-adolescents
5. HIV Epidemiology and Field Services Program. (2017). HIV surveillance annual report, 2017. Retrieved from https://www1.nyc.gov/assets/doh/downloads/pdf/dires/hiv-surveillance-annualreport-2017.pdf